Pacific Shuanglin Bio-pharmacy Co Current Liabilities
The Current Liabilities of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Oct 29, 2026 is 174.12 M CNY. In the previous year, Current Liabilities was 1.03 B CNY — a change of -83.04% (lower).
Get this data via API
Financial Data API
Current Liabilities
174.12 MCNY
YoY
-83.04%
Last updated:
The Pacific Shuanglin Bio-pharmacy Co Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 174.12 MCNY | -83.04% | |
| 1.03 BCNY | +3.21% | |
| 994.89 MCNY | +3.75% | |
| 958.89 MCNY | +42.18% | |
| 674.41 MCNY | -12.14% | |
| 767.60 MCNY | +133.08% | |
| 329.33 MCNY | -65.80% | |
| 962.92 MCNY | +27.52% | |
| 755.12 MCNY | +38.53% | |
| 545.12 MCNY | -41.10% | |
| 925.47 MCNY | +89.26% | |
| 488.99 MCNY | -6.13% | |
| 520.91 MCNY | -30.47% | |
| 749.15 MCNY | +20.48% | |
| 621.78 MCNY | +6.50% | |
| 583.86 MCNY | -41.11% | |
| 991.41 MCNY | +10.80% | |
| 894.79 MCNY | -48.70% | |
| 1.74 BCNY | +2.04% | |
| 1.71 BCNY | -10.73% | |
| 1.91 BCNY | +24.60% | |
| 1.54 BCNY | +27.60% | |
| 1.20 BCNY | +57.30% | |
| 765.63 MCNY | +4.06% | |
| 735.79 MCNY | +55.63% | |
| 472.78 MCNY | -2.02% | |
| 482.54 MCNY | +63.04% | |
| 295.96 MCNY | +64.83% | |
| 179.56 MCNY | +11.68% | |
| 160.78 MCNY | +66.82% | |
| 96.38 MCNY | -6.29% | |
| 102.85 MCNY | -5.92% | |
| 109.32 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pacific Shuanglin Bio-pharmacy Co Stock analysis
Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock
Current Liabilities of Pacific Shuanglin Bio-pharmacy Co is 174.12 M CNY in 2025.
Current Liabilities of Pacific Shuanglin Bio-pharmacy Co changed from 1.03 B CNY to 174.12 M CNY, representing a -83.04% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Pacific Shuanglin Bio-pharmacy Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Pacific Shuanglin Bio-pharmacy Co
All Key Metrics — Pacific Shuanglin Bio-pharmacy Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth